
Corvus Pharmaceuticals Inc CRVS.O:
CORVUS PHARMACEUTICALS ANNOUNCES FULL DATA FROM COHORT 3 OF PLACEBO-CONTROLLED PHASE 1 CLINICAL TRIAL OF SOQUELITINIB FOR ATOPIC DERMATITIS
CORVUS PHARMACEUTICALS INC - COHORT 3 SHOWS CLINICALLY MEANINGFUL REDUCTION IN ITCH BY DAY 8
CORVUS PHARMACEUTICALS INC - ALL COHORTS SHOW STATISTICALLY SIGNIFICANT DIFFERENCE FROM PLACEBO AT DAY 28
CORVUS PHARMACEUTICALS INC - COHORT 3 SHOWS EARLIER AND DEEPER RESPONSES COMPARED TO COHORTS 1-2